You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The molecular assay detects and differentiates Trichomonas vaginalis and/or Mycoplasma genitalium in clinical urine samples.
The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.
Abbott said that the MDx platform offers a number of initial assays, including tests for HIV-1, HBV, and HCV, among others.
The company unveiled forthcoming products for high-throughput molecular testing, diagnostic lab informatics, and microbiology automation.
The new women's health and STI tests for the BD Max platform are part of a small, focused panel approach which the firm believes will resonate with physicians and labs.
Solid MDx revenue growth was driven primarily by sales of Aptima women's health products on the Panther and Tigris platforms.
The firm said that molecular product sales were up 103 percent, driven by the launch of the Solana Group A Strep assay earlier this year.
The test detects chlamydia, gonorrhea, and trichomonas from a single patient sample.
Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.
The presentations were part of a Quidel-sponsored workshop and poster sessions at the Clinical Virology Symposium in Daytona Beach, Fla.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.